Biotricity Restructures Capital, Creating Highly Dilutive Series C Preferred Stock with 59.6% Conversion Trigger

summarizeSummary

Biotricity Inc. has restructured its capital by exchanging existing common stock, options, and warrants held by insiders for a new Series C Preferred Stock, which carries significant voting rights and will convert into 59.6% of common stock upon a future $15 million financing.

check_boxKey Events

• Capital Restructuring Completed

  Biotricity exchanged 14,144,325 common shares, 3,992,427 options, and 1,436,216 warrants for 1,957,297 shares of newly created Series C Preferred Stock. This includes securities held by officers and directors.

• Significant Potential Dilution

  The Series C Preferred Stock will automatically convert into an aggregate of 59.6% of the company's outstanding common stock upon the closing of any equity offering that raises at least $15 million.

• Enhanced Voting Rights

  Holders of Series C Preferred Stock are entitled to 40 votes for each share, granting them substantial influence over company matters.

• Incentive for Future Financing

  The conversion terms create a strong incentive for the company to pursue a large equity financing, which is critical given its prior 'going concern' disclosure.

auto_awesomeAnalysis

This 8-K details a significant capital restructuring where existing equity and derivatives, including those held by officers and directors, are converted into a new Series C Preferred Stock. The most critical aspect is the automatic conversion feature: if the company secures a "Qualified Financing" of at least $15 million, the Series C Preferred Stock will convert into a staggering 59.6% of the company's outstanding common stock. This mechanism provides a strong incentive for the company to raise substantial capital, likely to address its prior "going concern" status, but at a potentially severe dilutive cost to current common shareholders. The Series C Preferred Stock also grants 40 votes per share, giving holders significant control. Investors should be aware of the substantial dilution risk and the shift in control this restructuring represents.